Skinovation Pharmaceutical 10-Q 6 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 06, 2020
Document And Entity Information
Entity Registrant Name	SKINOVATION PHARMACEUTICAL INC
Entity Central Index Key	0001118072
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Entity Incorporation, State or Country Code	WY
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity File Number	000-30991
Is Entity's Reporting Status Current?	Yes
Entity Interactive Data Current	Yes
Is Entity Emerging Growth Company?	true
Elected Not To Use the Extended Transition Period	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Common Stock, Shares Outstanding		708,000
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Entity Shell Company	true

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current Assets
Cash	$ 4,752	$ 77
Total Current Assets	4,752	77
Total Assets	4,752	77
Current Liabilities
Accounts payable	10,500	7,200
Notes payable	224,521	212,321
Accrued interest	107,683	94,741
Total Current Liabilities	342,704	314,262
Total Liabilities	342,704	314,262
Stockholders' Deficit
Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding	708	708
Additional paid-in capital	25,148	25,148
Accumulated deficit	(363,808)	(340,041)
Total Stockholders' Deficit	(337,952)	(314,185)
Total Liabilities and Stockholders' Deficit	$ 4,752	$ 77

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	25,000,000	25,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	50,000,000	50,000,000
Common stock, issued	708,000	708,000
Common stock, outstanding	708,000	708,000

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
REVENUES
EXPENSES
General and administrative	2,700	2,715	10,825	10,840
TOTAL EXPENSES	2,700	2,715	10,825	10,840
INCOME (LOSS) BEFORE OTHER EXPENSE	(2,700)	(2,715)	(10,825)	(10,840)
OTHER INCOME (EXPENSE)
Interest expense	(4,448)	(4,085)	(12,942)	(12,058)
Total other income (expense)	(4,448)	(4,085)	(12,942)	(12,058)
INCOME (LOSS) BEFORE INCOME TAXES	(7,148)	(6,800)	(23,767)	(22,898)
INCOME TAXES
NET INCOME (LOSS)	$ (7,148)	$ (6,800)	$ (23,767)	$ (22,898)
Basic and diluted net income (loss) per share	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.03)
Weighted average shares outstanding	708,000	708,000	708,000	708,000

Statements of Stockholders_ Def

Statements of Stockholders’ Deficit (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Dec. 31, 2018	708,000
Beginning balance, amount at Dec. 31, 2018	$ 708	$ 25,148	$ (310,314)	$ (284,458)
Net loss			(9,367)	(9,367)
Ending balance, shares at Mar. 31, 2019	708,000
Ending balance, amount at Mar. 31, 2019	$ 708	25,148	(319,681)	(293,825)
Beginning balance, shares at Dec. 31, 2018	708,000
Beginning balance, amount at Dec. 31, 2018	$ 708	25,148	(310,314)	(284,458)
Net loss				(22,898)
Ending balance, shares at Sep. 30, 2019	708,000
Ending balance, amount at Sep. 30, 2019	$ 708	25,148	(333,212)	(307,356)
Beginning balance, shares at Mar. 31, 2019	708,000
Beginning balance, amount at Mar. 31, 2019	$ 708	25,148	(319,681)	(293,825)
Net loss			(6,731)	(6,731)
Ending balance, shares at Jun. 30, 2019	708,000
Ending balance, amount at Jun. 30, 2019	$ 708	25,148	(326,412)	(300,556)
Net loss			(6,800)	(6,800)
Ending balance, shares at Sep. 30, 2019	708,000
Ending balance, amount at Sep. 30, 2019	$ 708	25,148	(333,212)	(307,356)
Beginning balance, shares at Dec. 31, 2019	708,000
Beginning balance, amount at Dec. 31, 2019	$ 708	25,148	(340,041)	(314,185)
Net loss			(9,602)	(9,602)
Ending balance, shares at Mar. 31, 2020	708,000
Ending balance, amount at Mar. 31, 2020	$ 708	25,148	(349,643)	(323,787)
Beginning balance, shares at Dec. 31, 2019	708,000
Beginning balance, amount at Dec. 31, 2019	$ 708	25,148	(340,041)	(314,185)
Net loss				(23,767)
Ending balance, shares at Sep. 30, 2020	708,000
Ending balance, amount at Sep. 30, 2020	$ 708	25,148	(363,808)	(337,952)
Beginning balance, shares at Mar. 31, 2020	708,000
Beginning balance, amount at Mar. 31, 2020	$ 708	25,148	(349,643)	(323,787)
Net loss			(7,017)	(7,017)
Ending balance, shares at Jun. 30, 2020	708,000
Ending balance, amount at Jun. 30, 2020	$ 708	25,148	(356,660)	(330,804)
Net loss			(7,148)	(7,148)
Ending balance, shares at Sep. 30, 2020	708,000
Ending balance, amount at Sep. 30, 2020	$ 708	$ 25,148	$ (363,808)	$ (337,952)

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows from Operating Activities
Net income (loss)	$ (23,767)	$ (22,898)
Changes in assets and liabilities:
Increase in accounts payable	3,300	3,400
Increase in accrued interest	12,942	12,058
Net cash used by operating activities	(7,525)	(7,440)
Cash Flows from Investing Activities
Net cash used by investing activities
Cash Flows from Financing Activities
Proceeds from notes payable	12,200	7,400
Net cash provided by financing activities	12,200	7,400
Increase (decrease) in cash	4,675	(40)
Cash and cash equivalents at beginning of period	77	132
Cash and cash equivalents at end of period	4,752	92
Supplemental Cash Flow Information:
Cash paid for interest
Cash paid for income taxes

Condensed Financial Statements

Condensed Financial Statements	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Financial Statements	NOTE 1 – CONDENSED FINANCIAL STATEMENTS The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended September 30, 2020 and for all periods presented have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2019 audited financial statements as reported in its Form 10-K. The results of operations for the period ended September 30, 2020 are not necessarily indicative of the operating results for the full year ended December 31, 2020.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies. The COVID-19 pandemic could have an impact on our ability to obtain financing to fund our operations. The Company is unable to predict the ultimate impact at this time.

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
NOTES PAYABLE	NOTE 3 – NOTES PAYABLE During the nine months ended September 30, 2020, a third party loaned the Company $12,200. The notes bear interest at 8% and are due on demand. Notes payable at September 30, 2020 and December 31, 2019 were $224,521 and $212,321, respectively. Accrued interest on the notes was $107,683 and $94,741 at September 30, 2020 and December 31, 2019, respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 4 – SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Loan from third party	$ 12,200
Notes payable	$ 224,521	$ 212,321
Interest rate on accounts payable-converted note	8.00%
Accrued interest on notes	$ 107,683	$ 94,741